High Level of Blood Eosinophils and Localization of Bronchiectasis in Patients with Severe Asthma: A Pilot Study

Background. Severe asthma and bronchiectasis are heterogeneous diseases that frequently coexist. The location of bronchiectasis is generally determined by specific underlying pathophysiological mechanisms. The aim of this study was to determine whether in a population suffering from both severe asthma and bronchiectasis there was a correlation between eosinophilic inflammation and localization of bronchiectasis. Methods. We enrolled 41 patients with coexisting bronchiectasis from eight different severe asthma center outpatient clinics and collected the following data: baseline characteristics, Asthma Control Test, Asthma Control Questionnaire, IgE level, blood count, high-resolution computed tomography and bronchiectasis-related parameters, skin prick test, FeNO50 and flow-volume spirometry. The study was retrospectively registered. Results. The presence of eosinophils > 1000 cells/μL was related to distribution of lower pulmonary bronchiectasis (9.1% upper lobes vs. 53.3% lower lobes, p = 0.014). Indeed, the presence of eosinophilic counts > 1000 increased the probability of lower localization of bronchiectasis compared to upper lobes (ODD 0.088 (0.010–0.772), p = 0.028). Conclusions. An increase in blood eosinophils > 1000 cells/μL seems to be associated with lower preferential localization of bronchiectasis with sparing of the upper lung lobes. This could represent a new potential radiological phenotype that could have a dedicated therapeutic strategy in the future.

[1]  F. Blasi,et al.  T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis , 2021, Biomedicines.

[2]  R. Intravaia,et al.  Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot study. , 2021, Respiratory medicine.

[3]  Todor A Popov,et al.  The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians , 2020, Journal of clinical medicine.

[4]  J. Costa,et al.  Eosinophils: a biological marker for bronchiectasis exacerbations? , 2019, Respiratory infections.

[5]  G. E. Carpagnano,et al.  Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab , 2019, Journal of asthma and allergy.

[6]  K. Nakagome,et al.  Involvement and Possible Role of Eosinophils in Asthma Exacerbation , 2018, Front. Immunol..

[7]  J. Chalmers,et al.  Peripheral blood eosinophilia and clinical phenotype in Bronchiectasis , 2018, Respiratory infections.

[8]  P. Flume,et al.  Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity , 2018, The Lancet.

[9]  M. Miravitlles,et al.  The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions , 2018, European Respiratory Journal.

[10]  G. Canonica,et al.  Type 2 immunity in asthma , 2018, The World Allergy Organization journal.

[11]  S. Loukides,et al.  The role of non‐invasive modalities for assessing inflammation in patients with non‐cystic fibrosis bronchiectasis , 2017, Cytokine.

[12]  T. Welte,et al.  European Respiratory Society guidelines for the management of adult bronchiectasis , 2017, European Respiratory Journal.

[13]  G. Dale,et al.  The Role of Neutrophil Elastase Inhibitors in Lung Diseases. , 2017, Chest.

[14]  Travis S Henry,et al.  Bronchiectasis: Mechanisms and Imaging Clues of Associated Common and Uncommon Diseases. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.

[15]  H. Mitchison,et al.  Diagnosis and management of primary ciliary dyskinesia , 2014, Archives of Disease in Childhood.

[16]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[17]  J. Bousquet,et al.  Practical guide to skin prick tests in allergy to aeroallergens , 2012, Allergy.

[18]  Margaret W Leigh,et al.  An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. , 2011, American journal of respiratory and critical care medicine.

[19]  P. Giavina-Bianchi,et al.  Comorbidities in Severe Asthma: Frequency of Rhinitis, Nasal Polyposis, Gastroesophageal Reflux Disease, Vocal Cord Dysfunction and Bronchiectasis , 2009, Clinics.

[20]  Wai-ming Lee,et al.  Basal cells of differentiated bronchial epithelium are more susceptible to rhinovirus infection. , 2008, American journal of respiratory cell and molecular biology.

[21]  R. Stockley,et al.  Prevalence and Impact of Bronchiectasis in α1-Antitrypsin Deficiency , 2007 .

[22]  S. Wenzel.  Asthma: defining of the persistent adult phenotypes , 2006, The Lancet.

[23]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[24]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[25]  ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. , 2005, American journal of respiratory and critical care medicine.

[26]  S. Durham,et al.  Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis , 1998, Thorax.

[27]  Y. Fukuchi,et al.  Importance of diffuse aspiration bronchiolitis caused by chronic occult aspiration in the elderly. , 1996, Chest.

[28]  W. Busse,et al.  Eosinophil adhesion to vascular cell adhesion molecule-1 activates superoxide anion generation. , 1995, Journal of immunology.